{"id":52457,"date":"2023-01-03T01:02:16","date_gmt":"2023-01-03T00:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/"},"modified":"2023-01-03T01:02:16","modified_gmt":"2023-01-03T00:02:16","slug":"biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/","title":{"rendered":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement"},"content":{"rendered":"
\n

BEIJING & SHANGHAI–(BUSINESS WIRE)–#Antibody<\/a>–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice\u2122 Platforms and Hansoh Pharmaceutical Group Company Limited (\u201cHansoh Pharma\u201d, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen\u2019s Project Integrum programs and generated from our proprietary fully human antibody RenMice\u2122 target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,\u201d said Dr. Yuelei Shen, President and CEO of Biocytogen. \u201cThanks to Hansoh Pharma\u2019s recognition of our RenMice\u2122 platforms and Project Integrum. We believe Hansoh Pharma\u2019s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMice\u2122-derived antibody molecules and bring the benefits to patients worldwide.\u201d\n<\/p>\n

\nAbout Project Integrum<\/b>\n<\/p>\n

\nProject Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMice\u2122 (RenMab\u2122, RenLite\u00ae<\/sup> and RenNano\u00ae<\/sup>) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo<\/i> drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMice\u2122 KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companys to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.\n<\/p>\n

\nAbout Biocytogen:<\/b>\n<\/p>\n

\nBiocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab\u2122\/RenLite\u00ae<\/sup>\/RenNano\u00ae<\/sup> mice platforms for fully human monoclonal, bispecific\/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo<\/i> drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and\/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice\u2122 licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http:\/\/en.biocytogen.com.cn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBiocytogen\u2019s Contacts:<\/b>
Antibody assets and platforms: BD-Licensing@biocytogen.com<\/a>
Media: pr@bbctg.com.cn<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING & SHANGHAI–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice\u2122 Platforms and Hansoh Pharmaceutical Group Company Limited (\u201cHansoh Pharma\u201d, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52457","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING & SHANGHAI–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice\u2122 Platforms and Hansoh Pharmaceutical Group Company Limited (\u201cHansoh Pharma\u201d, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T00:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement\",\"datePublished\":\"2023-01-03T00:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/\"},\"wordCount\":562,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230102005064\\\/en\\\/1674765\\\/21\\\/LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/\",\"name\":\"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230102005064\\\/en\\\/1674765\\\/21\\\/LOGO.jpg\",\"datePublished\":\"2023-01-03T00:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230102005064\\\/en\\\/1674765\\\/21\\\/LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230102005064\\\/en\\\/1674765\\\/21\\\/LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend","og_description":"BEIJING & SHANGHAI–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice\u2122 Platforms and Hansoh Pharmaceutical Group Company Limited (\u201cHansoh Pharma\u201d, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T00:02:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement","datePublished":"2023-01-03T00:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/"},"wordCount":562,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/","name":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg","datePublished":"2023-01-03T00:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230102005064\/en\/1674765\/21\/LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-and-hansoh-pharma-announce-an-antibody-license-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen and Hansoh Pharma Announce an Antibody License Agreement"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52457"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52457\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}